Maxacalcitol, a vitamin D3 analog, acts as a potent orally active VDR agonist with minimal calcemic effects. It inhibits PTH mRNA expression and bone resorption, making it a promising candidate for hyperparathyroidism research. Additionally, Maxacalcitol exhibits anti-tumor activity by suppressing cell proliferation, migration, and inducing apoptosis through GPx-1 inhibition. Its unique properties suggest potential utility in treating psoriasis and underscore its significance in bone health and cancer research.